Inactive Instrument

Other languages Nascent Biotech, Inc. Other OTC

Equities

NBIO

US63108Q1013

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	04-17
Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	04-16
Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	03-19
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14
Nascent Biotech and Manhattan Biosolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates	02-06
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is significantly under Valued	01-10
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk	12-20
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer	23-08-22
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-18
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	23-07-02
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-29
Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement	23-05-30
Nascent Biotech : Termination of Material Agreement - Form 8-K	23-05-30
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-05-09
Nascent Biotech, Inc. Announces the Completion of Its Phase1 Clinical Trials	23-02-28
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERTIONS (form 10-Q)	23-02-14
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-01-26
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial	23-01-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nascent Biotech, Inc. Other OTC

Equities

NBIO

US63108Q1013

Other languages

Filters